KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Gains from Investment Securities (2017 - 2025)

Twist Bioscience (TWST) has disclosed Gains from Investment Securities for 7 consecutive years, with -$11.0 million as the latest value for Q3 2023.

  • On a quarterly basis, Gains from Investment Securities changed N/A to -$11.0 million in Q3 2023 year-over-year; TTM through Sep 2023 was -$6.8 million, a N/A change, with the full-year FY2025 number at $683000.0, up 168.71% from a year prior.
  • Gains from Investment Securities was -$11.0 million for Q3 2023 at Twist Bioscience, down from $4.1 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $33.6 million in Q3 2021 to a low of -$11.0 million in Q3 2023.
  • A 5-year average of $1.5 million and a median of $41419.5 in 2019 define the central range for Gains from Investment Securities.
  • Biggest YoY gain for Gains from Investment Securities was 64650.0% in 2022; the steepest drop was 4416.88% in 2022.
  • Twist Bioscience's Gains from Investment Securities stood at $44000.0 in 2019, then skyrocketed by 84.09% to $81000.0 in 2020, then tumbled by 587.65% to -$395000.0 in 2021, then fell by 26.33% to -$499000.0 in 2022, then tumbled by 2104.41% to -$11.0 million in 2023.
  • Per Business Quant, the three most recent readings for TWST's Gains from Investment Securities are -$11.0 million (Q3 2023), $4.1 million (Q2 2023), and $636000.0 (Q1 2023).